ReviewCancer science2009
Molecularly targeted therapy for hepatocellular carcinoma.
Review in Cancer science, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 101 citations in OpenAlex.
- Sorafenib enhances effects of transarterial chemoembolization for hepatocellular carcinoma: a systematic review and meta-analysis.Journal of cancer research and clinical oncology · 2014Pooled it
- Transarterial chemoembolization combined with sorafenib versus monotherapy for unresectable hepatocellular carcinoma: An umbrella review of meta-analyses.Canadian liver journal · 2026Review
- Targeting TCF21-TCF3 heterodimer in tumor-associated pericytes attenuates hematogenous metastasis by restoring pericyte gatekeeper function.Cell reports. Medicine · 2026Article
- Injectable nanocomposite hydrogels for targeted intervention in cancer, wound healing, and bone and myocardial tissue engineering.Drug delivery and translational research · 2025Review
- Hyaluronic-Acid-Coated Sterosome for Dasatinib Delivery in Hepatocellular Carcinoma: Preparation, Physicochemical Characterization, and In Vitro Evaluation.Biomimetics (Basel, Switzerland) · 2025Article
- NSUN2-mediated mRNA mGenomics, proteomics & bioinformatics · 2023Article
- Knockdown of THOC1 reduces the proliferation of hepatocellular carcinoma and increases the sensitivity to cisplatin.Journal of experimental & clinical cancer research : CR · 2020Article
- Azido-galactose outperforms azido-mannose for metabolic labeling and targeting of hepatocellular carcinoma.Biomaterials science · 2019Article
- CD133 expression and α-fetoprotein levels define novel prognostic subtypes of HBV-associated hepatocellular carcinoma: A long-term follow-up analysis.Oncology letters · 2018Article
- Precision medicine based on surgical oncology in the era of genome-scale analysis and genome editing technology.Annals of gastroenterological surgery · 2018Review
- Detection of MicroRNA in Hepatic Cirrhosis and Hepatocellular Carcinoma in Hepatitis C Genotype-4 in Egyptian Patients.BioMed research international · 2017Article
- Detection of ALDH1 activity in rabbit hepatic VX2 tumors and isolation of ALDH1 positive cancer stem cells.Journal of translational medicine · 2016Article
- Use of VEGFR-2 targeted ultrasound contrast agent for the early evaluation of response to sorafenib in a mouse model of hepatocellular carcinoma.Molecular imaging and biology · 2015Article
- Comparison of systems for assessment of post-therapeutic response to sorafenib for hepatocellular carcinoma.Journal of gastroenterology · 2014Article
- Targeting the insulin-like growth factor pathway in hepatocellular carcinoma.World journal of hepatology · 2014Review
- MicroRNAs in nonalcoholic fatty liver disease: novel biomarkers and prognostic tools during the transition from steatosis to hepatocarcinoma.BioMed research international · 2014Review
- Molecular mechanisms of action and potential biomarkers of growth inhibition of dasatinib (BMS-354825) on hepatocellular carcinoma cells.BMC cancer · 2013Article
- Sorafenib and its derivative SC-49 sensitize hepatocellular carcinoma cells to CS-1008, a humanized anti-TNFRSF10B (DR5) antibody.British journal of pharmacology · 2013Article
- Antiproliferative small-molecule inhibitors of transcription factor LSF reveal oncogene addiction to LSF in hepatocellular carcinoma.Proceedings of the National Academy of Sciences of the United States of America · 2012Article
- Epithelial mesenchymal transition and hedgehog signaling activation are associated with chemoresistance and invasion of hepatoma subpopulations.Journal of hepatology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Accumulated understanding of the molecular pathways regulating cancer progression has led to the development of novel targeted therapies. Hepatocellular carcinoma (HCC) remains a highly lethal disease that is resistant to conventional cytotoxic chemotherapy and radiotherapy. Unlike conventional chemotherapy, molecular-targeted agents offer the potential advantages of a relatively high therapeutic window and use in combination with other anticancer strategies without overlapping toxicity. It is hoped that these drugs will become valuable therapeutic tools within the multimodal approach to treating cancer. A recent clinical trial revealed an oral multikinase inhibitor, sorafenib, as the first agent that has demonstrated improved overall survival in patients with advanced HCC. The present review summarizes molecular abnormalities of HCC with a focus on clinical studies, and current status as well as problems of the targeted strategies for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.